Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients

Gligorov, KAZIM; Ataseven, B.; Verrill, M.; De laurentiis, M.; Jung, K.; Azim, H.; Al-Sakaff, N.; Lauer, S.; Shing, M.; Pivot, X.

doi:10.1016/j.ejca.2017.05.010

Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients

Atıf İçin Kopyala

Gligorov J., Ataseven B., Verrill M., De laurentiis M., Jung K. H., Azim H. A., ...Daha Fazla

EUROPEAN JOURNAL OF CANCER, cilt.82, ss.237-246, 2017 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 82
Basım Tarihi: 2017
Doi Numarası: 10.1016/j.ejca.2017.05.010
Dergi Adı: EUROPEAN JOURNAL OF CANCER
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.237-246
Anahtar Kelimeler: Adjuvant, Breast cancer, HER2/neu, Herceptin, Subcutaneous, Trastuzumab, OPEN-LABEL, CHEMOTHERAPY, DOXORUBICIN, PACLITAXEL, PREFHER, HANNAH
Kocaeli Üniversitesi Adresli: Evet

Özet

Aim: To assess the safety and tolerability of adjuvant subcutaneous trastuzumab (Herceptin (R) SC, H SC), delivered from an H SC Vial via hand-held syringe (Cohort A) or single-use injection device (Cohort B), with or without chemotherapy, for human epidermal growth factor receptor 2 (HER2)-positive stage I to IIIC early breast cancer (EBC) in the phase III SafeHer study (NCT01566721).